129 related articles for article (PubMed ID: 19287975)
1. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
McHugh LA; Sayan AE; Mejlvang J; Griffiths TR; Sun Y; Manson MM; Tulchinsky E; Mellon JK; Kriajevska M
Int J Oncol; 2009 Apr; 34(4):1155-63. PubMed ID: 19287975
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
McHugh LA; Kriajevska M; Mellon JK; Griffiths TR
Urology; 2007 Feb; 69(2):390-4. PubMed ID: 17320695
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Mu Y; Sun D
Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
[TBL] [Abstract][Full Text] [Related]
5. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
7. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract][Full Text] [Related]
8. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Powles T; Huddart RA; Elliott T; Sarker SJ; Ackerman C; Jones R; Hussain S; Crabb S; Jagdev S; Chester J; Hilman S; Beresford M; Macdonald G; Santhanam S; Frew JA; Stockdale A; Hughes S; Berney D; Chowdhury S
J Clin Oncol; 2017 Jan; 35(1):48-55. PubMed ID: 28034079
[TBL] [Abstract][Full Text] [Related]
9. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
11. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
Burris HA
Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
[TBL] [Abstract][Full Text] [Related]
12. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
13. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
15. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
16. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Havaleshko DM; Smith SC; Cho H; Cheon S; Owens CR; Lee JK; Liotta LA; Espina V; Wulfkuhle JD; Petricoin EF; Theodorescu D
Neoplasia; 2009 Nov; 11(11):1185-93. PubMed ID: 19881954
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
[TBL] [Abstract][Full Text] [Related]
19. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
de Martino M; Zhuang D; Klatte T; Rieken M; Rouprêt M; Xylinas E; Clozel T; Krzywinski M; Elemento O; Shariat SF
Cancer Biol Ther; 2014 Sep; 15(9):1239-47. PubMed ID: 24971884
[TBL] [Abstract][Full Text] [Related]
20. EGFR and HER2 inhibition in pancreatic cancer.
Walsh N; Kennedy S; Larkin A; Corkery B; O'Driscoll L; Clynes M; Crown J; O'Donovan N
Invest New Drugs; 2013 Jun; 31(3):558-66. PubMed ID: 23076814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
